AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 32 min read$AXSM

Axsome Therapeutics Inc (AXSM) (Q3 2026) Earnings Call Highlights: Revenue Tops $1 Billion

Axsome Therapeutics reported Q3 2026 revenue of $259.7M, up 52% YoY, with AUVELITY sales at $207.6M. Net loss narrowed to $12.9M. Growth driven by demand in MDD and Alzheimer's disease agitation. Pipeline includes 10 programs with near-term catalysts. Expenses rose due to commercialization efforts, and stock is down 40-45% since launch.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 1:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 1:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Axsome Therapeutics Inc (AXSM) (Q3 2026) Earnings Call Highlights: Revenue Tops $1 Billion — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$AXSMBullishMed
01

Why it matters

The earnings beat provides a fresh catalyst for the stock, potentially prompting a price rally.

02

Market read

Earnings surprise may attract short-term buying interest in AXSM.

03

What to watch

Potential headwinds from payer coverage gaps and inventory levels may temper near-term gains.

Relevance 7/10Novelty 8/10Timing: after-hours

Background

Axsome Therapeutics reported its Q3 2026 earnings, highlighting significant revenue growth and loss reduction.

Company-level read

Ticker impact

$AXSMBullishHigh confidence
Context

Q3 2026 earnings call disclosed revenue of $259.7M, up 52% YoY, and net loss narrowing to $12.9M.

Expected impact

likely upward pressure as investors price in revenue beat and improved loss profile

Evidence & confidence

Revenue exceeded expectations and loss narrowed significantly, providing a clear catalyst for buying interest.

Market effects

Sector

Strong performance may boost sentiment in the neuropsychiatric biotech sector.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

Despite revenue growth, high gross-to-net discounts and slow adoption could limit upside.

Key entities

  • Company
    Axsome Therapeutics Inc

    Biopharma company developing treatments for CNS disorders.

Read at source← All news

StoryAxsome Therapeutics posts Q3 2026 revenue beat and sharply reduced loss

Also covered by

4 outlets

Related articles

NOV 3
$AXSMMed

Axsome Therapeutics Earnings Call Signals Broad Growth

Axsome Therapeutics (AXSM) reported Q3 revenue of $260M, up 52% YoY. AUVELITY sales rose 53% YoY to $208M, while SUNOSI revenue increased 47% YoY to $48.2M. Net loss narrowed to $12.9M from $47.2M YoY. The company cited growth in prescriptions and prescribers, but noted concerns like higher expenses and limited SYMBRAVO coverage.

tipranks.com3 min
NOV 2
$AXSMMedAI 8/10

Axsome Therapeutics, Inc. Q3 2026 Earnings Call Summary

Axsome Therapeutics reported Q3 2026 revenue growth of 52% YoY, driven by AUVELITY's performance in MDD and ADA, with total revenue surpassing $1B annually. Net loss narrowed to $12.9M due to operating leverage. AUVELITY saw sequential growth, with primary care prescribers being a key driver. The company maintained a gross margin in the low to mid-90% range. Management expects continued growth and sufficient cash to reach cash flow positivity.

finance.yahoo.com2 min
NOV 2
$AXSMMedAI 8/10

Axsome (AXSM) Q3 2026 Earnings Call Transcript

Axsome (AXSM) reported Q3 2026 revenue of $260M, up 52% YoY. AUVELITY sales grew 53% YoY to $208M, while SUNOSI revenue increased 47% YoY to $48.2M. Net loss narrowed to $12.9M from $47.2M YoY. The company highlighted strong prescription growth for AUVELITY, particularly in Alzheimer's agitation and major depressive disorder indications, and expects continued momentum. SYMBRAVO sales also grew 88% YoY to $3.9M. The company maintains a strong cash position and anticipates cash flow positivity.

finance.yahoo.com2 min